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Background: Peroxisome proliferator-activated receptor gamma (PPARγ) has direct and indirect function in adipokines
production process. We aimed to assess the possible influence of circulating PPARγ on relative risk of metabolic
syndrome and also examine the association between circulating PPARγ and adipokines levels among obese subjects.
Methods: A total of 96 obese subjects (body mass index (BMI) ≥30) were included in the current cross-sectional
study. We assessed the body composition with the use of Body Composition Analyzer BC-418MA - Tanita. The MetS
(metabolic syndrome) was defined based on the National Cholesterol Education Program Adult Treatment Panel
III. All baseline blood samples were obtained following an overnight fasting. Serum concentrations of adipokines
including Retinol binding protein 4 (RBP4), omentin-1, vaspin, progranulin, nesfatin-1 and circulating PPARγ was
measured with the use of an enzyme-linked immunosorbent assay method. Statistical analyses were performed
using software package used for statistical analysis (SPSS).
Results: We found main association between circulating PPARγ and body composition in obese population. The risk of
metabolic syndrome in subjects with higher concentration of PPARγ was 1.9 fold in compared with lower concentration
of PPARγ after adjustment for age, sex and BMI. There was significant association between PPARγ and adipokines,
specially nesfatin-1 and progranulin. Defined adipokines pattern among participants demonstrated the markedly higher
concentration of vaspin, RBP4 and nesfatin-1 in participants with MetS compared to non-MetS subjects.
Conclusions: It appears all of studied adipokines might have association with PPARγ level and might simultaneously
be involve in some common pathway to make susceptible obese subjects for MetS.
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The possibility of having metabolic irregularities, including
Metabolic Syndrome (MetS), develops with the level of
obesity. Obese subjects with MetS had significantly
increased risk of mortality compared to without MetS
[1]. Although, the underlying mechanisms of obesity's
influence on MetS development are not completely under-
stood; but compelling evidences suggested the main effect
of adipokines in this procedure [2,3].* Correspondence: jalalimahmoud@hotmail.com
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reproduction in any medium, provided the orAdipokines, with important endocrine functions expresses
and secretes factors from adipose tissue [4]. Among
numerous secreted adipokines, some of them including
nesfatin-1 [5], retinol binding protein 4 (RBP4) [6],
omentin-1 [7], vaspin [8], and progranulin [9], provide an
extensive network of communication both within adipose
tissue and are implicated directly in the pathologies
associated with metabolic syndrome [10].
The MetS was defined based on the National Cholesterol
Education Program Adult Treatment Panel III criteria as
presenting at least three of the following components: 1)
waist circumferences 102 cm or greater in men or 88 cm
or greater in women; 2) triglycerides 1.7 mmol/liter
(150 mg/dl) or greater; 3) high density lipoprotein (HDL)Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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less than 1.29 mmol/liter (50 mg/dl) in women; 4) blood
pressure 130/85 mm Hg or greater or current use of anti-
hypertensive medications; or 5) fasting plasma glucose
6.1 mmol/liter (110 mg/dl) or greater [11].
The most important determinant of adipokine secretion
depends on mature adipocyte size and circulating levels
of adipokines verified by average size of adipocytes [12].
Compelling evidences demonstrated the essential role of
Peroxisome proliferator-activated receptor gamma (PPARγ)
in the formation [13] and size [14] of adipocytes. PPARγ
as a member of the nuclear receptor superfamily of ligand-
activated transcription factor has direct [15] and indirect
[13,14,16] function in adipokines production process.
Moreover, there are some evidences that activation of
PPARγ pathway [17] through involvement on changes of
adipokines could affect on metabolic profiles in animal
model of metabolic syndrome studies [18]. In humans,
PPARγ is expressed by peripheral cells such as lympho-
cytes and monocytes [19-22]. The widespread tissue
distribution of PPARγ [23] and unknown pathway of
the target tissue(s) of circulating synthetic agonists of
PPARγ [24] suggests an involvement of the nuclear recep-
tor in multiple peripheral processes. It has been reported
that there are balance between nuclear hormone receptor
superfamily including PPARγ and proper lipid ligand and
target PPARγ drug in peripheral circulation [24,25]. In view
of the fact that assessment of circulating PPARγ ligands
could clarify some pathway of PPARγ function, so it seems
that evaluation of PPARγ concentration similar to its
agonist concentration in plasma would be benefit to find
its correlation with some important process in metabolism
and adipokines secretion. Although, PPARγ genotypes
considered as modulator factor in MetS risk in previous
studies [26-28], but there was not any reports regarding to
association between circulating PPARγ and susceptibility
to MetS in obesity. Accordingly, we design current study
to assess the possible influence of circulating PPARγ on
relative risk of metabolic syndrome and also examine the
association between various levels of PPARγ and different
pattern of circulating adipokines among obese subjects.
Methods
Study population
A total of 96 obese subjects were included in the current
cross-sectional study from October of 2011 to January of
2012. The proportion of the men was 18.75% (n = 18) and
that of the women was 81.25% (n = 78) in current study's
population. All of participants were obese (body mass
index (BMI) ≥30). The study was approved by the local
ethics committee of the Tehran University of Medical
Sciences. Patients were selected according to the defined
inclusion criteria which were: BMI ≥30, age 20–50 years,
absence of any acute or chronic inflammatory disease, nomedical history of hypertension, no alcohol or drug abuse,
no use of PPARγ agonist or antagonist, vitamin, dietary,
herbal or omega-3 supplements for at least 3 months prior
to the study period and not being pregnant or menopause.
Exclusion criteria were: history of any condition affecting
inflammatory markers such as known cardiovascular
diseases, thyroid diseases, malignancies, current smoking,
diabetes mellitus, sustained hypertension, heart failure,
acute or chronic infections, and hepatic or renal diseases.
Sedentary subjects, with restrictive diet and non-normolip-
idemic were also excluded of the study. First step for
analyzing, we categorized all of participants according to
median of PPARγ concentration to low and high concen-
tration of PPARγ groups. We next used regression model
for calculating the possible risk of MetS according to
PPARγ level. All participants gave written informed consent
before any study procedure was performed. We performed
all of measurements including blood pressure, biochemical
and hormonal test, resting metabolic rate and body
composition analysis for all of study's participants. Insulin
resistance (IR) was calculated by homeostasis model assess-
ment (HOMA). The HOMAIR was calculated according to
IRHOMA= [Fasting Plasma Glucose (mmol/L) × Fasting
Plasma Insulin (mIU/L)] /22.5 [29]. The BAI is calculated
as: (100x hip circumference in m/ height in m x √height)-
18. The waist circumference (WC) was measured at the
midpoint between the lower border of the rib cage and
the iliac crest by using a flexible inch tape.
Blood pressure measurement
We measured the blood pressure by Automatic Inflate
Blood Pressure Monitor (Samsung BA507S automatic
digital blood pressure monitor, Samsung America, Inc.)
according to manufacturer's instructions in the sitting
position of all participants. The blood pressure of all
participants was measured after 15-min rest in the chair-
seated position by the same person.
Complete body composition analysis
We assessed the body composition of all cases with the
use of Body Composition Analyzer BC-418MA - Tanita
(United Kingdom). This equipment is designed send out a
very weak electric current to measure the impedance
(electrical resistance) of the body. Therefore, in principle,
subjects were barefoot when they were assessed by this de-
vice. Moreover, since impedance fluctuates in accordance
with the distribution of the body fluid, we followed all of
the following instructions for an accurate measurement.
To prevent a possible discrepancy in measured values, we
avoided taking measurements after vigorous exercise and
waited until the subject was sufficiently rested. To prevent
inaccurately low body fat percentage measurements
and other measurement errors, we always held both arms
straight down when taking measurements. As changes in
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major impact on measurements, they were performed
in the morning in a fasting condition (always urinating
before taking measurements, etc.) to get a more accurate
result of the measurements every single time. The device
calculates body fat percentage, fat mass, and fat free mass
and predicts muscle mass on the basis of data using
Bioelectrical Impedance Analysis (BIA). The main outputs
of device are BMI, Fat%, Fat mass, FFM, TBW and visceral
fat levels. Through the use of 8 electrodes, the Body
Composition Analyzer makes it possible to show separate
body composition mass for the right arm, the left arm, the
trunk, the right leg and the left leg. We were reported
trunk fat along with other important body composition
components including fat percent, fat mass, free fat mass
and visceral fat in current study.
RMR measurements
Measurements were performed on all subjects by profes-
sional nutritionists using a standard protocol that described
in details previously [30]. Resting Metabolic Rate (RMR)
was measured by means of the MetaCheck™ (Korr Medical
Technologies, Salt Lake City, Utah), an instrument de-
signed to measure RMR using indirect calorimetry. Indirect
calorimetry is a method of calculating metabolic rate from
the measured the amount of oxygen consumed by the
body. Using the MetaCheck mouthpiece, the individual
being tested breathes in room air and the gas the person
breathes out, is conveyed to the MetaCheck through the
breathing hose. The MetaCheck analyzes the volumetric
flow and oxygen concentration of the expired gas to deter-
mine the amount of oxygen consumed by the body due to
metabolism. RMR was measured by indirect calorimetry
following an overnight period of 10–12 hour fasting.
Subjects were required to fast and remain in a resting
state for 12 hours prior to the test and to abstain from
smoking ≥ 4 hour before the commencement of the
procedure although the ideal interval was 12 h so that
to ensure the body was in a resting and post-absorptive
state. Patients were instructed to rest in supine position
on a mattress for 15 minutes and then they underwent the
measurement for a period of 20 minutes. However, the
first 5 minutes was not included and only the last
15 minutes were used to calculate RMR.
Definition of the MetS
The MetS was defined based on the National Cholesterol
Education Program Adult Treatment Panel III criteria [11]
described completely in previous section [11].
Biochemical parameters and hormonal assay
Patients fasted for 12 hours before peripheral venous
blood was collected from the patients. All baseline blood
samples were obtained between 8:00 and 10:00 am. Serumwas centrifuged, aliquoted and stored at a temperature
of −80ºC. All samples were analyzed by means of a single
assay. Glucose Oxidase Phenol 4-Aminoantipyrine Perox-
idase (GOD/PAP) method was used for the measurement
of fasting serum glucose, and, triglyceride levels were
measured by Glycerol-3-phosphate oxidase Phenol
4-Aminoantipyrine Peroxidase (GPO-PAP) method. Total
cholesterol levels were measured by Enzymatic Endpoint
method, and direct high and low density lipoprotein
was measured by enzymatic clearance assay. Fasting
serum glucose and lipid profile measurements were
done with the use of Randox laboratories kit (Hitachi
902). Liver function test including Aspartate transaminase
(AST), alkaline phosphatase (ALP) and alanine aminotran-
ferease (ALT) were measured using an automatic analysis
system (Autoanalyzer; Hitachi Ltd, Tokyo, Japan) with Ran-
dox laboratories kit. All inter-assay calculated coefficients
of variation were within the normal range of enzymatic kits
data sheets. Serum Hyper sensitivity C-reactive protein
(hsCRP), was measured by means of a imonoturbidimetric
assay (High sensitivity assay, by Hitachi 902). Serum insulin
concentrations were measured by enzyme-linked immuno-
sorbent assay (ELISA) method (Human insulin ELISA
kit, DRG Pharmaceuticals, GmbH, Germany) minimum
detectable concentration was 1.76 μlU/ml, Intra CV was
2.19% and Inter CV was 4.4%.
Circulating adipokines measurements
Serum concentrations of all adipokines were measured
in triplicate and 10 replicates per ELISA plate were used
as internal quality controls. RBP4 in serum samples was
measured by competitive enzyme-linked immunosorbent
assay (ELISA) (AdipoGen, Seoul, Korea) and inter- and
intra-assay variability were 4.2% and 4.5%, respectively
(Cat. No. R0822EK). Serum Omentin 1 [Intelectin-1 (hu-
man) ELISA Kit] was measured using an ELISA (Enzo Life
Sciences; sensitivity: 0.4 ng/ml; reference range: 0.5 –32 ng/
ml inter-assay variability: 4.61%; intra-assay variability: 5.2%)
(Cat. No. APO-54 N-034). Vaspin (human) ELISA Kit (Enzo
Life Sciences; sensitivity: 0.01 ng/ml; inter-assay variability:
5.8%; intra-assay variability: 6.5%) (Cat. No. ALX-850-375).
Serum progranulin was measured with the use of an ELISA
method (AdipoGen; Seoul, Korea; sensitivity: 32 pg/ml;
inter-assay variability: 4.7%; intra-assay variability: 3.79%)
(Cat. No. AG-45A-0018EK-KI01). Circulating PPARγ was
assayed by Human peroxisome proliferator-activated recep-
tor γ (PPAR-γ) ELISA Kit (CUSABIO BIOTECH, China)
sensitivity: 19.53 pg/ml.; detection range: 78.13 pg/ml-
5000 pg/ml, inter-assay precision: 6.8%; intra-assay preci-
sion: 5.6%) (Cat. No. CSB-E08623h). Circulating nesfatin-1
was assayed by Human Nesfatin-1 ELISA Kit (CUSABIO
BIOTECH, China) sensitivity: 7.8 pg/ml; detection range:
31.25 pg/ml-2000 pg/ml, inter-assay precision: 7.8%; intra-
assay precision: 6.6%) (Cat. No. CSB-E15050h).
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Normal distribution of data was assured using Kolmogrov-
Smirnov. Baseline characteristics and anthropometric mea-
surements of obese participants according to low and high
PPARγ level were assessed by Independent- Samples T
Test. Categorical variables were compared using chi-square.
We used Binary Logistic regression model for calculating
the possible risk of MetS according to PPARγ level as only
covariates in model 1, and after included age and gender
as covariates in model 2; age, gender and BMI as covariates
in model 3; and age, gender, BMI and finally body compos-
ition components (fat mass and free fat mass) as covariates
in model 4. We used Bivariate correlations analysis to find
correlation among various adipokines and PPARγ. Finally,
we performed the factor analysis (Principal Component
Analysis) for defining the pattern of adipokines change inTable 1 Baseline characteristics and anthropometric measure
PPARγ level
Characteristics Low circulating
PPARγ (Mean ± SEM) ¶†
High circu
PPARγ (Mean
Age (year) 40.68 ± 1.65 37.44 ±
Weight(kg) 88.54 ± 1.64 97.92 ±
BMI (kg/m2) 34.26 ± 0.56 36.42 ±
Fat (%) 40.73 ± 0.86 40.82 ±
Fat mass (kg) 36.27 ± 1.14 39.72 ±
FFM (kg) 52.48 ± 1.13 58.21 ±
Visceral Fat (kg) 10.57 ± 0.53 11.48 ±
Trunk Fat 18.09 ± 0.52 20.37 ±
FBS (mg/dl) 103.13 ± 3.73 113.11 ±
TG (mg/dl) 130.90 ± 8.14 162.65 ±
Total Chol (mg/dl) 188.41 ± 4.97 195.91 ±
HDL Chol (mg/dl) 49.93 ± 1.30 47.46 ±
LDL Chol (mg/dl) 100.40 ± 3.39 103.93 ±
AST (IU/L) 16.73 ± 1.03 19.56 ±
ALT(IU/L) 14.42 ± 1.59 16.45 ±
ALP(IU/L) 179.50 ± 6.67 185.22 ±
Hs-CRP (mg/l) 3.11 ± 0.41 3.68 ± 0
Insulin (μlU/ml) 16.99 ± 1.03 18.36 ±
HOMA-IR 4.43 ± 0.38 5.31 ± 3
RMR (kcal/24 h) 1542.77 ± 56.79 1880.97 ±
BAI 39.22 ± 0.75 39.40 ±
WC (cm) 97.87 ± 1.31 105.26 ±
SBP (mmhg) 124.95 ± 3.90 123.06 ±
DBP (mmhg) 86.65 ± 1.89 83.71 ±
*P-value ≤0.05 are significant.
†Independent- Samples T Test.
¶Mean plus and minus Standard Error Mean.
†n of participants in low circulating PPARγ group = 48, n of participants in high circ
BMI, body mass index; FFM, free fat mass; FBS, fasting blood sugar; TG, triglyceride,
transaminase; ALT, alanine aminotransferase; ALP, Alkaline phosphatase; hsCRP, Hig
- Insulin Resistance; RMR, resting metabolic rate; BAI, Body Adiposity Index; WC, Waobese subjects and then examine its effect on MetS risk.
Data were expressed as mean ± Sd. Error Mean (SEM).
The level of significance was set at a probability of ≤0.05
for all tests. Statistical analyses were performed using SPSS
version 18.0 (SPSS Inc., Chicago, IL).
Results
Baseline characteristics of obese participants according
to circulating PPARγ
Baseline characteristics and anthropometric measurements
of obese participants according to circulating PPARγ level
was demonstrated in Table 1. As shown in this table we
found significant differences on weight (pvalue = 0.003),
BMI (pvalue = 0.013), fat mass (pvalue = 0.05), Free fat
mass (FFM) (pvalue = 0.018), trunk fat (pvalue = 0.008),




of the difference (Lower- Upper)
P value†
1.69 −1.47 to 7.95 0.176
2.56 −15.41 to-3.35 0.003*
0.64 −3.86 to −0.46 0.013*
0.98 −2.70 to 2.51 0.945
1.30 −6.88 to 0.003 0.050*
2.08 −10.43 to −1.01 0.018*
0.51 −2.38 to 0.55 0.221
0.65 −3.95 to −0.60 0.008*
6.56 −24.90 to 4.93 0.191
11.18 −59.26 to −4.22 0.025*
4.50 −20.84 to 5.85 0.267
1.45 −1.40 to 6.34 0.210
3.02 −12.57 to 5.50 0.439
1.14 −5.89 to 0.22 0.069
1.76 −6.75 to 2.68 0.395
6.55 −24.32 to12.87 0.542
.47 −1.81 to 0.67 0.368
1.24 −4.57 to 1.85 0.402
.52 −2.21 to 0.44 0.19
84.04 −538.98 to-137.41 0.001*
0.86 −2.45 to 2.10 0.88
1.60 −11.51 to −3.26 0.001*
2.98 −7.85 to11.62 0.702
2.07 −2.63 to 8.53 0.296
ulating PPARγ group = 48.
LDL, low density lipoprotein; HDL, high density lipoprotein; AST, Aspartate
h sensitivity c-reactive protein, HOMA-IR, Homeostasis Model of Assessment
ist Circumference, SBP, systolic blood pressure, DBP, diastolic blood pressure.
Table 2 Risk of Metabolic syndrome and its components
may modify by circulating PPARγ in the obese subjects
Metabolic syndrome
and its components
Odd ratio 95% CI P
Metabolic syndrome‡
Model 1‖ 1.85 1.07-3.20 0.02
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circulating PPARγ. Our results demonstrated no significant
differences in fat percent, visceral fat, FBS, total cholesterol,
HDL and LDL cholesterol, evaluated liver enzymes,
hs-CRP, insulin, HOMA-IR, BAI, and blood pressure
(P > 0.05) between high and low levels of circulating PPARγ.Model 2¶ 2.05 1.14-3.67 0.01
Model 3† 1.90 1.04-3.47 0.03
Model 4§ 1.88 1.01-3.49 0.04
Abdominal Obesity (WC)
Model 1 3.889 1.49-10.14 0.005
Model 2 5.069 1.66-15.43 0.004
Model 3 4.820 1.30-17.75 0.018
Model 4 5.199 1.07-25.26 0.04
Hyperglycemia*
Model 1 1.47 0.77-2.79 0.23
Model 2 1.55 0.80-2.99 0.18
Model 3 1.42 0.71-2.81 0.31
Model 4 1.39 0.67-2.88 0.37
Hypertension
Model 1 1.22 0.71-2.10 0.46
Model 2 1.49 0.71-3.14 0.28
Model 3 1.33 0.62-2.87 0.46
Model 4 1.15 0.51-2.61 0.72
Low HDL
Model 1 1.70 0.96-3.02 0.06
Model 2 1.71 0.95-3.06 0.07
Model 3 1.63 0.90-2.95 0.10
Model 4 1.62 0.89-2.95 0.11
Hypertriglyceridemia
Model 1 1.636 0.933-2.869 0.086
Model 2 1.706 0.957-3.042 0.070Circulating PPARγ in the obese subjects and the risk
of MetS and its components
Results of logistic regression model demonstrated the main
effect of circulating PPARγ on the risk of metabolic
syndrome and its components (Table 2). We found the
1.901 increased risk of metabolic syndrome in subjects
with higher concentration of PPARγ in compared with
lower concentration of PPARγ after adjustment for
age, sex and BMI (pvalue = 0.037, 95% CI from 1.041 to
3.473). We also found the 1.88 increased risk of metabolic
syndrome in subjects with higher concentration of PPARγ
in compared with lower concentration of PPARγ after
adjustment for age, sex , BMI and body composition
components (pvalue = 0.04, 95% CI from 1.01 to 3.49).
Analysis of the effect of PPARγ level on the relative
risk of MetS components demonstrated the significant
effect of circulating PPARγ on abdominal obesity. Accord-
ingly, the relative risk of abdominal obesity was increased
4.82 in subjects with higher concentration of PPARγ in
compared with lower concentration of PPARγ after adjust-
ment for age, sex and BMI (pvalue = 0.018, 95% CI from
1.30 to 17.75). Considering to other components of MetS,
there is not significant association between hyperglycemia
and hypertension relative risk and PPARγ level. We found
no significant association between the increased relative
risk to low HDL (pvalue = 0.071, 95% CI from 0.956 to
3.069) and hypertriglyceridemia (pvalue = 0.070, 95% CI
from 0.957 to 3.042) with high level of PPARγ after adjust-
ment for age and gender.Model 3 1.593 0.884-2.870 0.121
Model 4 1.545 0.84-2.83 0.16
Logistic regression model for circulating PPARγ effect on Risk of Metabolic
syndrome and its components.
Total n = 96, n of men =18, n of women = 78, mean of age = 39.06, mean
of BMI = 35.34.
The significant value presented by bold format.
‡The MetS was defined based on the National Cholesterol Education Program Adult
Treatment Panel III criteria as presenting at least three of the following components:
1) waist circumferences 102 cm or greater in men or 88 cm or greater in women; 2)
triglycerides 1.7 mmol/liter (150 mg/dl) or greater; 3) HDL cholesterol less than
1.03 mmol/liter (40 mg/dl) in men or less than 1.29 mmol/liter (50 mg/dl) in women;
4) blood pressure 130/85 mm Hg or greater or current use of antihypertensive
medications; or 5) fasting plasma glucose 6.1 mmol/liter (110 mg/dl) or greater.
‖Step 1 in Logistic regression model; MetS entered as dependent and
categorized PPARγ (low and high concentration of PPARγ based on median)
entered as covariates as a first model.
¶Age, gender entered on Step 1.
†Body Mass Index entered on Step 2.
§Body composition components including fat mass and FFM entered on
Step 3.
MetS, metabolic syndrome; WC, waist circumferences; HDL, high
density lipoprotein.Correlation between circulating adipokines and PPARγ,
Adipokines levels between low/high concentrations of
PPARγ and Adipokines pattern in MetS
We first examined the correlation between circulating
adipokines and PPARγ (Table 3). Our results demon-
strated positive correlation between circulating PPARγ
and nesfatin-1 level (r = 0.275, pvalue = 0.008). We also
observed the positive significant correlation between
circulating PPARγ and progranulin (r = 0.32, pvalue =
0.032). Consider to correlation of RBP4 (r = −0.353,
pvalue = 0.051), omentin-1 (r = 0.289, pvalue = 0.054) and
vaspin (r = −0.261, pvalue = 0.084) levels with PPARγ con-
centration; there was not significant correlation between
them. We couldn’t find significant correlation between
HOMA-IR as an insulin resistance index and PPARγ and
measured adipokines level in our study (pvalue >0.05).
Table 3 Correlation between circulating adipokines and PPARγ
Adipokinesζ Nesfatin-1 RBP4 Omentin Progranulin Vaspin PPARγ
Nesfatin-1 Pearson Correlation 1
Sig. (2-tailed) .
RBP4 Pearson Correlation −0.201 1
Sig. (2-tailed) 0.278 .
Omentin Pearson Correlation 0.171 −0.132 1
Sig. (2-tailed) 0.263 0.470
Progranulin Pearson Correlation 0.022 −0.238 0.379(*) 1
Sig. (2-tailed) 0.887 0.190 0.012 .
Sig. (2-tailed) 0.994 0.408 0.234 0.130
Vaspin Pearson Correlation 0.253 0.099 0.363(*) 0.238 1
Sig. (2-tailed) 0.094 0.589 0.014 0.119 .
PPARγ Pearson Correlation 0.275(**) −0.353 0.289 0.327(*) 0.261 1
Sig. (2-tailed) 0.008 0.051 0.054 0.032 0.084 .
**Correlation is significant at the 0.01 level (2-tailed).
*Correlation is significant at the 0.05 level (2-tailed).
ζCorrelation analysis performed by log 10 adipokines levels.
Pearson correlation analysis performed between circulating nesfatin-1, RBP4, omentin, progranulin, vaspin and PPARγ.
Total n = 96, n of men =18, n of women = 78, mean of age = 39.06, mean of BMI = 35.34.
The significant value presented by bold format.
RBP4, retinol binding protein 4; PPARγ, Peroxisome proliferator-activated receptor gamma.
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between categorized PPARγ levels in low/high groups; our
results demonstrated the significant higher concentration
of nesfatin-1 in group with high level of PPARγ. There
are not significant differences in RBP4 (pvalue = 0.29),
omentin-1 (pvalue = 0.12), and vaspin (pvalue = 0.13)
levels between high vs, low PPARγ concentration groups.
We found not significant differences in circulating pro-
granulin between groups with diverse level of PPARγ
(pvalue = 0.07) (Figure 1).
For completing our analysis consider finding pattern
of adipokines changes in MetS; we do the factor analysis.
Accordingly, we design principle component analysis to
extract one pattern of adipokines levels among participants
with MetS and healthy (Figure 2). We found markedly
higher concentration of vaspin, RBP4 and nesfatin-1 in
participants with MetS compared to non-MetS subjects.
Discussion
This study demonstrated the main association between
circulating PPARγ and body composition in obese popu-
lation. The risk of metabolic syndrome in subjects with
higher concentration of PPARγ was higher in compared
with lower concentration of PPARγ after adjustment for
age, sex and BMI. We found significant association between
PPARγ and adipokines, specially nesfatin-1 and progranu-
lin. Also, according to defined adipokines pattern among
participants, we found markedly higher concentration
of vaspin, RBP4 and nesfatin-1 in participants with MetS
compared to non-MetS subjects.PPARγ is a ligand-activated transcription factor that
considered as a main regulator of adipocyte differentiation
[15]. We found the higher levels of weight, BMI, fat mass,
FFM and trunk fat among participants with higher concen-
tration of PPARγ. The effect of PPARγ agonist on average
fat cell size in the epididymal fat pad reported from animal
model study. Results of mentioned study revealed the
smaller average fat cell size in untreated PPARγ+/− animals
compared with wild-type (WT) littermates and was sig-
nificantly increased after treatment with PPARγ agonist to
values comparable to those of controls [31]. Evidences of
Kubota et al. [32] study on PPARγ receptor-deficient mice
did not display adipocyte hypertrophy. It has been sug-
gested that the primary action of troglitazone as PPARγ
agonist may be to increase the number of small adipocytes
in white adipose tissues, presumably via PPARγ [14]. It
has been shown that moderate reduction of PPARγ with a
retinoid X receptor (RXR) antagonist or a PPARγ antag-
onist decreases triglyceride (TG) content in white adipose
tissue, skeletal muscle and liver. These inhibitors changed
the some adipokines effects, which increases fatty acid
combustion and energy dissipation, thereby ameliorating
HF diet-induced obesity [33]. The simultaneous markedly
difference in TG level and fat composition between
groups with various circulating PPARγ in our research
may be related to explained mechanism by Kadowaki
et al. [33] study.
It has been demonstrated that the agonist of PPARγ,
rosiglitazone, improves the metabolic profile and changes
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Figure 1 Independent- Samples T Test analysis performed to detect differences in circulating nesfatin-1, RBP4, omentin, progranulin,
vaspin between low/high concentrations of PPARγ. Total n = 96, n of men =18, n of women = 78, mean of age = 39.06, mean of BMI = 35.34,
RBP4, retinol binding protein 4; PPARγ, Peroxisome proliferator-activated receptor gamma.
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profiles in animal model of MetS. Current study's findings
demonstrated that the obese subjects with higher concen-
tration of PPARγ were more susceptible to categorize in
MetS group. We observed that in obese people who had
more concentration of PPARγ the risk of MetS was
increasing in compare to obese people who had lower
concentration of PPARγ. In compare to animal model of
MetS, the observed raised concentration of PPARγ may
act as compensatory mechanism to affect on adipokines
levels and other metabolism profile to improve the some
MetS outcomes.
There are evidences [34] that a 50% reduction in content
of PPARγ receptor did not result in insulin resistance, as
one might predict, but rather led to an increase in insulin
sensitivity. As a result, it has been suggested that PPARγdeficiency might prevent or attenuate the insulin resistance
associated with obesity and other factors. Therefore, due to
relative PPARγ deficiency mitigates some physiological
causes of insulin resistance, so make a condition as thera-
peutic maneuver with aimed to produce the same effect as
PPARγ deficiency. Thus, this status could be of clinical
value in the treatment of insulin resistance [31] as strongly
contributor of obesity and other components of the
MetS [35].
Our results demonstrated no significant differences in
HOMA-IR values between groups with low and high
level of PPARγ. However, HOMA-IR has been widely
used in various studies, but hardly has consensus on the
cut-off points for classification of insulin resistance [36].
An existing hesitation is the clinical value of HOMA-IR






















Figure 2 Factor analysis (Principal Component Analysis)
performed for defining the pattern of adipokines change in
obese subjects with and without MetS. The markedly higher
concentration of vaspin, RBP4 and nesfatin-1 was seen in participants
with MetS compared to non-MetS subjects. Total n = 96, n of men = 18,
n of women = 78, mean of age = 39.06, mean of BMI = 35.34, MetS,
metabolic syndrome; RBP4, retinol binding protein 4; PPARγ,
Peroxisome proliferator-activated receptor gamma.
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http://www.dmsjournal.com/content/5/1/79[36]. The major limitation of the use of HOMA-IR index
in studies is that the model applies values calculated from
lean young adults of Caucasian origin as standard to other
subjects [37,38]. Utilization of values for other population
including older adults [39] or obese subjects would prob-
ably be different from those documented for previous
studies. So, it seems that obese individuals are known to
be reasonably more insulin resistant [40]. The ethnicity
also considered as a main factor in the etiology of insulin
resistance [41]. Previous published results considering cut-
off points for HOMA-IR in healthy subjects of our studied
community demonstrated values less than observed in
current study [36] that likelihood was related to increased
insulin resistance in obese individuals. Therefore, the not
significant differences in insulin resistance between groups
may explain through increased of HOMA-IR value in all
of participants and not have defined cut-off points for
studied groups.
It has been demonstrated that PPARγ play a key role
in the regulation of inflammation and other immune
responses [42]. Although, some studies have suggested the
contrary findings considering PPARγ role in inflammation
status, but it is reported that PPAR activation is associated
with anti-inflammatory responses [43]. Despite these
evidences, our results demonstrated no significant differ-
ences in hs-CRP and liver enzymes between different
categorized level of PPARγ groups.
Nesfatin-1 has been implicated in appetite regulation,
weight loss and/or malnutrition [44]. Endogenous pancre-
atic islet nucleobindin 2 (NUCB2)/nesfatin is altered in
diabetes and diet-induced obesity [45]. Previous studies
observed positive correlations between nesfatin-1 and BMI,
percent of body fat and the triceps skinfold thickness[44]. Percent of body fat was demonstrated as the main
determinant of nesfatin-1 variance [44]. It seems that our
findings consider to significant association between PPARγ
level and circulating nesfatin-1 might be consistence with
mentioned evidences due to main correlation between
circulating PPARγ and fat mass. Another confirming
data to justify the markedly correlation between PPARγ
and nesfatin-1 demonstrated by Yamada et al. research that
interestingly, nesfatin-1, derived from the precursor pep-
tide, NUCB2, from a troglitazone, PPARγ ligand, induced
cDNA library [46].
Progranulin has been introduced as an adipokine indu-
cing insulin resistance and obesity [9]. Although, current
study's findings demonstrated the main association between
this adipokine and circulating PPARγ, but to our know-
ledge, there is not supporting information to explain
observed correlation.
According to some evidences, there are possible mech-
anisms that influencing diseases related to obesity and
therapeutic opportunities for them through PPARγ and
several adipokines such as vaspin and RBP4 [16]. There
is evidences that confirmed an association of increased
circulating RBP4 levels and the metabolic syndrome [47].
There are evidences that RBP4 gene expression is induced
in brown fat from mice treated with PPAR agonists.
PPARγ can also induce the RBP4 gene in white adipocytes.
As a result, it has been concluded that PPARγ-mediated
signaling controls RBP4 gene expression through dependent
mechanism to PPAR and its co-activators [48]. In view of
that, the observed marginal correlation between PPARγ
and RBP4 might explain via referred mechanisms from
Rosell et al. [48] study.
Plasma omentin-1 levels, were correlated inversely
with obesity [49]. However, results of clinical study
demonstrated the pioglitazone as PPARγ agonist reduced
omentin-1 levels in women [50], but we couldn’t find the
significant correlation between circulating PPARγ and
omentin-1 levels.
Vaspin, visceral adipose tissue-derived serpin, was
originally identified as an adipokine, which were found
to be associated with obesity in humans [51]. Evidences
from previous studies demonstrated that vaspin mRNA
increased with treatment of PPARγ agonist, pioglitazone
[2]. We found the marginal positive correlation between
PPARγ and this adipokine. Similar to PPARγ, it has been
suggested that vaspin might be the compensatory molecule
in the pathogenesis of MetS and vaspin-mimicking agents
or vaspin recombinant protein might have beneficial effect
on MetS improvement [2]. So, it appears all of studied
adipokines might have association with PPARγ level and
might simultaneously be involve in some common pathway
to make susceptible obese subjects for MetS and other
obesity related condition. In this regard, there are com-
pelling evidences from previous studies for supporting
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http://www.dmsjournal.com/content/5/1/79some of our findings, and need to more research to de-
scribe new findings in current study.
A number of caveats need to be considered in interpret-
ation of present findings. Briefly, the relatively small sample
size might limit the power to detect precise association
between some adipokines and PPARγ. In addition, con-
founding might exist and influence our analyses. However,
we did adjust for the important factors that may affect
circulating PPARγ. We acknowledge experimental studies
that replication in a diverse population is required to verify
our findings.
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